KROMATID Names Matthew Hemstreet CEO as Company Advances Toward Market Leadership in Cell & Gene Therapy

BOULDER, Colo., June 18, 2026 /PRNewswire/ -- KROMATID, a leader in structural genomic integrity analysis for the cell and gene therapy industry, today announced the appointment of Matthew Hemstreet as Chief Executive Officer, succeeding Interim CEO Terry Opgenorth. KROMATID announces...

Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.